

David Z Qian

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11276054/publications.pdf>

Version: 2024-02-01

29
papers

3,331
citations

257450

24
h-index

526287

27
g-index

30
all docs

30
docs citations

30
times ranked

5503
citing authors

#	ARTICLE	IF	CITATIONS
1	HIF1 and ID1 Interplay Confers Adaptive Survival to HIF1 α -Inhibition. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 724059.	3.7	0
2	Molecular Crosstalk Between MYC and HIF in Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 590576.	3.7	50
3	Interplay between hypoxia and androgen controls a metabolic switch conferring resistance to androgen/AR-targeted therapy. <i>Nature Communications</i> , 2018, 9, 4972.	12.8	40
4	Systemic Inhibition of CREB is Well-tolerated in vivo. <i>Scientific Reports</i> , 2016, 6, 34513.	3.3	46
5	Identification of a Potent Inhibitor of CREB-Mediated Gene Transcription with Efficacious in Vivo Anticancer Activity. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 5075-5087.	6.4	120
6	Functional regulation of hypoxia inducible factor-1 α by SET9 lysine methyltransferase. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2015, 1853, 881-891.	4.1	26
7	Carbohydrate-conjugated fluorescent silica nanoprobe for selective detection of galectin-1 and prostate cancer cells. <i>Science Letters Journal</i> , 2015, 4, .	0.0	1
8	Malate dehydrogenase 2 confers docetaxel resistance via regulations of JNK signaling and oxidative metabolism. <i>Prostate</i> , 2013, 73, 1028-1037.	2.3	52
9	HIF1 α Protein Stability Is Increased by Acetylation at Lysine 709. <i>Journal of Biological Chemistry</i> , 2012, 287, 35496-35505.	3.4	123
10	HDAC4 Protein Regulates HIF1 α Protein Lysine Acetylation and Cancer Cell Response to Hypoxia. <i>Journal of Biological Chemistry</i> , 2011, 286, 38095-38102.	3.4	169
11	A HIF-Regulated VHL-PTP1B-Src Signaling Axis Identifies a Therapeutic Target in Renal Cell Carcinoma. <i>Science Translational Medicine</i> , 2011, 3, 85ra47.	12.4	54
12	CCL2 is induced by chemotherapy and protects prostate cancer cells from docetaxel-induced cytotoxicity. <i>Prostate</i> , 2010, 70, 433-442.	2.3	98
13	ID1 Enhances Docetaxel Cytotoxicity in Prostate Cancer Cells through Inhibition of p21. <i>Cancer Research</i> , 2010, 70, 3239-3248.	0.9	109
14	Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 17910-17915.	7.1	426
15	Prostate Cancer-Associated Gene Expression Alterations Determined from Needle Biopsies. <i>Clinical Cancer Research</i> , 2009, 15, 3135-3142.	7.0	15
16	Combination Strategy Targeting the Hypoxia Inducible Factor-1 α with Mammalian Target of Rapamycin and Histone Deacetylase Inhibitors. <i>Clinical Cancer Research</i> , 2008, 14, 3589-3597.	7.0	105
17	Digoxin and other cardiac glycosides inhibit HIF-1 α synthesis and block tumor growth. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 19579-19586.	7.1	568
18	The Iroquois Homeobox Gene 5 Is Regulated by 1,25-Dihydroxyvitamin D3 in Human Prostate Cancer and Regulates Apoptosis and the Cell Cycle in LNCaP Prostate Cancer Cells. <i>Clinical Cancer Research</i> , 2008, 14, 3562-3570.	7.0	55

#	ARTICLE	IF	CITATIONS
19	Platelets Take Up the Monoclonal Antibody Bevacizumab. <i>Clinical Cancer Research</i> , 2007, 13, 5341-5347.	7.0	105
20	Vascular Endothelial Growth Factor Trap Blocks Tumor Growth, Metastasis Formation, and Vascular Leakage in an Orthotopic Murine Renal Cell Cancer Model. <i>Clinical Cancer Research</i> , 2007, 13, 4201-4208.	7.0	111
21	Antitumor effect of the histone deacetylase inhibitor LAQ824 in combination with 13-cis-retinoic acid in human malignant melanoma. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 70-81.	4.1	74
22	Antitumor activity of the histone deacetylase inhibitor MS-275 in prostate cancer models. <i>Prostate</i> , 2007, 67, 1182-1193.	2.3	65
23	Sequence-dependent antitumor effects of differentiation agents in combination with cell cycle-dependent cytotoxic drugs. <i>Cancer Chemotherapy and Pharmacology</i> , 2007, 60, 329-339.	2.3	21
24	Class II Histone Deacetylases Are Associated with VHL-Independent Regulation of Hypoxia-Inducible Factor 1 α . <i>Cancer Research</i> , 2006, 66, 8814-8821.	0.9	292
25	Targeting Tumor Angiogenesis with Histone Deacetylase Inhibitors: the Hydroxamic Acid Derivative LBH589. <i>Clinical Cancer Research</i> , 2006, 12, 634-642.	7.0	264
26	Can Post-Transcription Modifiers Change the Course of Prostate Cancer?. <i>Translational Medicine Series</i> , 2006, , 179-194.	0.0	0
27	In vivo imaging of retinoic acid receptor β 2 transcriptional activation by the histone deacetylase inhibitor MS-275 in retinoid-resistant prostate cancer cells. <i>Prostate</i> , 2005, 64, 20-28.	2.3	37
28	Epigenetic Modulation of Retinoic Acid Receptor β 2 by the Histone Deacetylase Inhibitor MS-275 in Human Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2005, 11, 3535-3542.	7.0	76
29	The Histone Deacetylase Inhibitor NVP-LAQ824 Inhibits Angiogenesis and Has a Greater Antitumor Effect in Combination with the Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor PTK787/ZK222584. <i>Cancer Research</i> , 2004, 64, 6626-6634.	0.9	229